Search
Coherus BioSciences Inc
CHRSAdd to Watchlist
1.320USD
-0.010-0.75%
Close 08-20 16:00（ET）
202.36MMarket Cap
0.80P/E TTM
Forecast
Currency: USD Updated: 2026-08-19The current earnings forecast score of Coherus BioSciences Inc is 8.57, ranking 27 out of 158 in the Pharmaceuticals industry. The average price target is 5.00, with a high of 6.00 and a low of 4.00.
Analyst Rating
Based on
6
analysts
Buy
Current Rating
7.000
Target Price
+422.39%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
160
Total
6
Median
9
Average
Company name
Ratings
Analysts
Coherus BioSciences Inc
CHRS
6
Amgen Inc
AMGN
37
Biogen Inc
BIIB
37
Eli Lilly and Co
LLY
34
AbbVie Inc
ABBV
33
Regeneron Pharmaceuticals Inc
REGN
32
1
2
3
...
32
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Coherus BioSciences Inc's expected revenue for the next quarter?
Coherus BioSciences Inc's expected revenue is 16.01M.
What is Coherus BioSciences Inc's price target?
Analysts forecast that Coherus BioSciences Inc's price target is USD 5.00, with the highest forecast at USD 6.00 and the lowest forecast at USD 4.00.
How have Coherus BioSciences IncCHRS's recent earnings per share performed?
The market expectation was USD -0.13, while Coherus BioSciences IncCHRS's earnings per share (EPS) for the previous quarter was USD -0.28. EPS for the next quarter is expected at USD -0.22.
What is the analyst rating for Coherus BioSciences Inc?
Based on the ratings of Coherus BioSciences Inc's stock from 6 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.